Table of Contents

For years, Americans have paid some of the highest prices in the world for Ozempic. Now, with generic semaglutide available in Canada starting at $199.99 per pen, they have a new way to access treatment at a fraction of the cost.

Health Canada authorized the country’s first generic alternative on April 28, 2026. The approval was granted to Indian drugmaker Dr. Reddy’s Laboratories, following a thorough review confirming that the product meets safety, efficacy, and quality standards. Multiple drug makers had submitted applications to Health Canada following a patent lapse, and with data exclusivity ending in January 2026, approvals have now begun.

Here’s how the process works.

Key Takeaways

  • On April 28, 2026, Health Canada approved the country’s first generic semaglutide, made by India’s Dr. Reddy’s Laboratories.
  • Multiple companies have also applied to Health Canada, including Sandoz, Apotex, Teva, Taro, Aspen, and Vimy.
  • Authorized generics (Plosbrio and Poviztra) by Novo Nordisk were approved on December 22, 2025. They may offer some savings, but they may still be more expensive than third-party generics.

Brand-name semaglutide products

Semaglutide is marketed under various brand names, each intended for different uses.

Brand name Indication Dosage form List price in the US* Our price Notes
Ozempic Type 2 diabetes Once-weekly injection pen $1,027.51 $329.95 Widely prescribed off-label for weight loss.
Wegovy Chronic weight management Once-weekly injection pen $1,349.02 $599 Same active ingredient as Ozempic, but available in higher doses.
Wegovy HD Chronic weight management Once-weekly injection pen $1,349.02 – A high-dose version (7.2 mg) meant for existing Wegovy users who have been taking the 2.4 mg dose for at least four weeks and have reached a weight-loss plateau or require additional weight loss.
Wegovy tablets Chronic weight management Daily oral tablet $1,349.02 – Higher dose oral semaglutide (up to 25 mg) for weight management.
Rybelsus Type 2 diabetes Daily oral tablet $1,027.51 $298 Oral semaglutide for type 2 diabetes.
Plosbrio / Poviztra Type 2 diabetes / chronic weight management Once-weekly injection pens Pricing not yet publicly disclosed – Authorized generics of Ozempic/Wegovy by Novo Nordisk; approved in Canada on Dec 22, 2025.
*List price as of April 2026 source from https://www.novopricing.com/

Authorized generics vs. true generics of semaglutide

Before the first third-party generics arrive, Novo Nordisk Canada has already secured approval for authorized generics of Ozempic and Wegovy under the names Plosbrio and Poviztra.

Authorized generics are identical to the brand but sold under a different name at a lower price. Health Canada approved these products on December 22, 2025, but the market launch date for the products has not been announced.

In an emailed statement, Novo Nordisk Canada spokesperson Kate Hanna said the company is “considering introducing its own version of semaglutide to compete with generics when they enter the Canadian market.”

While the final price is unknown, authorized generics typically carry modest discounts because they are still produced by the original manufacturer. As competition arrives from independent generic companies, prices should fall further.

Why Canada gets generic semaglutide first

generic semaglutide in canada release date and price

In most countries, patents on semaglutide protect Novo Nordisk’s monopoly until the early 2030s. However, in Canada, a series of unusual events opened the door for generic competition.

Novo Nordisk held a Canadian patent, CA 2601784, covering semaglutide, but in 2018 and 2019, the company failed to pay annual maintenance fees. According to sources, the company missed a payment of CAD $250 plus a late fee of CAD $200 (total $450) in 2019. The Canadian patent office allowed a one-year grace period, but Novo still did not pay. As a result, the patent permanently lapsed in 2020, years earlier than expected.

This lapse did not immediately allow generic sales because Canada also grants eight years of data exclusivity after a new drug’s approval. During this period, generic manufacturers cannot rely on the brand’s clinical trial data.

For semaglutide, data exclusivity lasted until January 4, 2026. Once this date passed, generic companies were free to submit applications using Novo Nordisk’s data.

When will semaglutide become generic in the US?

The timing of generic semaglutide availability in the United States remains uncertain and may depend on patent protections, regulatory exclusivities, and other legal or commercial factors. Patent information for semaglutide-containing products such as Ozempic and Wegovy indicates that certain protections may extend into the 2030s, although timelines can change based on future developments.

Patients should also be aware that compounded semaglutide products are not FDA-approved generic versions of semaglutide. The FDA has stated that compounded drugs do not undergo the same premarket review process as FDA-approved medications and has issued communications regarding the marketing of certain compounded and unapproved semaglutide products.

For the most current information on generic availability, patients should consult their healthcare provider, pharmacist, or official FDA resources.

Buy Generic Semaglutide from Canada

Starts from $199.99

Order While Stock Lasts

Demand for generic semaglutide is expected to be high, which could affect future availability. If you’re interested in making the switch, now is a good time to order while inventory is available and pricing remains competitive.

SAVE 10% with coupon code:

How to get generic semaglutide from Canada online

How to buy generic Ozempic from Canada to the US online

You can easily follow our standard online ordering process.

Step 1. Search for “Generic semaglutide”

Use the search bar at the top of the website to search for “generic semaglutide.” Once you’re on the product page, select your prescribed dose (0.25 mg, 0.5 mg, or 1 mg) and click “Add to Cart.”

If you’d like to add additional medications, simply use the search bar to find them and add them to your cart. We carry a wide range of GLP-1 medications, including brand-name Ozempic, Wegovy, Mounjaro, and Zepbound. We also offer pen needles compatible with generic semaglutide pens.

Once you’ve added all of your medications and supplies, click the “Cart” button in the upper-right corner of the screen to proceed to checkout.

Step 2. Complete secure checkout

Once your cart is complete, proceed to checkout. Enter your contact details, payment information, and shipping address.

New customers will need to create an account using an email address and password. Remember to save 10% on your first order using coupon code FIRST10. Existing customers can log in with their current account details.

After submitting the order, you should receive a confirmation email.

Step 3. Upload, email, or fax your prescription

For prescription medications, we require a valid prescription before the order can be processed. You can send your prescription in one of three ways.

    • Upload it directly on the website using the RX document uploader after placing your order.
    • Email a clear scanned copy or photo of your prescription to info@buycanadianinsulin.com.
    • Fax your prescription to 1-888-234-1275.

If your prescription is not on file when the team reviews your prescription order, BuyCanadianInsulin.com may contact you to request the required documentation.

Step 4. Wait for your generic semaglutide package to arrive

Once a pharmacist reviews your order, eligible prescription orders can be processed for delivery. Tracking information is emailed when available so you can follow your shipment.

Which companies are making generic semaglutide?

Several pharmaceutical companies have filed generic submissions with Health Canada. Here is an overview of the main players and their publicly stated plans:

    • Sandoz Canada Incorporated – The first company to publicly announce its intention to launch generic semaglutide in Canada.
    • Aspen Pharmacare Canada Inc. – Another major generics manufacturer. The CEO said the company expected to register its semaglutide in Canada in late Q2 or Q3 2026 and planned to manufacture it in South Africa and France.
    • Apotex Inc – A Canadian generics giant, with submissions in 2025. They received approval from Health Canada in May 2026, and launched Apo-Semaglutide Injection in 2 mg and 4 mg prefilled pen formats.
    • Teva Canada Limited – Filed in August 2025. No publicly available timeline, but expected to be among the early entrants.
    • Taro Pharmaceuticals Inc – Submitted in June 2025.
    • Vimy Pharma – A newly-formed Toronto-based pharmaceutical startup founded by former Novo Nordisk executives. No publicly available submission date.

With so many companies vying to enter the market, competition should intensify quickly once the first approval is granted.

Bottom line

Generic semaglutide is finally available in Canada, giving Americans access to a lower-cost alternative to Ozempic. With prices starting at just $199.99 per pen and savings of more than $2,500 on a 3-month supply, many patients are looking north of the border for affordable treatment.

Frequently Asked Questions

Analysts offer two theories. One suggests the company simply missed the maintenance fee, an unusual administrative error. Another theory suggests the patent lapse was intentional, noting that large pharmaceutical companies rarely miss maintenance fees due to strict safeguards. They suggest Novo Nordisk may have allowed the lapse to avoid Canada’s PMPRB price controls, betting that pricing freedom would be more profitable than retaining a few extra years of patent protection.

Health Canada requires that generics have the same active ingredient, strength, dosage form, and route of administration as the brand. However, there may be minor differences in excipients (inactive ingredients), manufacturing processes, or injection devices. Health Canada will only approve generics that have demonstrated equivalent safety and efficacy. You may notice different packaging or pen design, but the clinical effects should be similar.

Some countries, such as India and China, may have generic semaglutide earlier than Canada because of different patent rules. However, importing medications from overseas carries legal risks and quality concerns. It is safer to rely on Health Canada-approved generics from reputable manufacturers or to obtain authorized generics through legitimate US channels when available.

Authorized generics usually come with small discounts. Since Novo Nordisk still makes them, they may not be much cheaper than Ozempic. Bigger savings will likely come from independent generics. Still, authorized generics could help patients save a bit if they need the medication sooner.

Coverage varies by insurer. Many insurance plans in Canada exclude weight-management drugs. However, once generics reduce the cost, insurers may reconsider coverage. Some private insurers have already signaled interest in covering GLP-1 drugs for obesity when more affordable options become available. In the US, insurers may negotiate with Novo Nordisk or consider coverage of authorized generics. It’s best to check with your insurance provider.

Articles you may also be interested in

Sources

Details for: PLOSBRIO. (2026, April 28). Drug and Health Products Portal. https://dhpp.hpfb-dgpsa.ca/dhpp/resource/106680

Details for: POVIZTRA. (2026, April 28). Drug and Health Products Portal. https://dhpp.hpfb-dgpsa.ca/dhpp/resource/106686

Health Canada. (2026, March 20). Generic submissions under review. Canada.ca. https://www.canada.ca/en/health-canada/services/drug-health-product-review-approval/generic-submissions-under-review.html

Lowe, D. (2025, June 10). Novo Nordisk’s Canadian mistake. Science | AAAS. https://www.science.org/content/blog-post/novo-nordisk-s-canadian-mistake

Satija, B., & Fick, M. (2025, November 12). Sandoz sees unbranded versions of Ozempic launching in Canada by end-June 2026. Reuters. https://www.reuters.com/business/healthcare-pharmaceuticals/sandoz-ceo-expects-ozempic-biosimilars-enter-canadian-market-q1-q2-2025-11-12/

Levi, J., Cross, S., Ramesh, N., Venter, F., & Hill, A. (2026). How low could semaglutide prices fall? An analysis of production cost and implications for global access ahead of patent expiry. medRxiv. https://doi.org/10.64898/2026.03.04.26347508

Andrei, M. (2026, March 10). Semaglutide could cost as little as $28 by the end of the year. ZME Science. https://www.zmescience.com/science/ozempic-patent-expiry-price-drop-2026/

Generic drugs | pCPA. (n.d.). https://www.pcpacanada.ca/generic-drug-framework

Dludla, N. (2026, March 3). Aspen Pharmacare expects Canada entry with Ozempic generic by third quarter. Reuters. https://www.reuters.com/business/healthcare-pharmaceuticals/aspen-pharmacare-aims-canada-entry-with-ozempic-generic-by-third-quarter-2026-03-03/

The Canadian Press. (2026, January 7). Novo Nordisk considers competing with generics through renamed lower-price Ozempic. CTVNews. https://www.ctvnews.ca/business/article/novo-nordisk-considers-competing-with-generics-through-renamed-lower-price-ozempic/